Recent actions in the A-share market are ongoing. In the biopharmaceutical sector, Rongchang Biotech has reached an licensing agreement with AbbVie, with a potential milestone payment of up to $4.95 billion; Haixiang Pharmaceutical has partnered with Wanbangde Pharmaceutical on an innovative drug project for ALS.

In terms of industrial upgrading, Jinlongyu Investment is investing 1.2 billion yuan to build an annual production line of 2GWh solid-state batteries, positioning itself in the new energy sector; Lanjian Electronics plans to acquire no less than 51% of Chengdu Xinying to expand into the chip design industry chain; Shudian Co., Ltd. plans to invest $300 million in a high-density optoelectronic integrated circuit board project.

On the capital side, Witeou has signed a strategic cooperation agreement with Qiteng Robotics, and Shunhao Co. has increased its investment of 74.98 million yuan in the joint-stock company Track Dawn. There are also notable developments in finance—Dongfang Wealth's subsidiary, Dongfang Wealth Securities, has been approved to publicly issue subordinate corporate bonds not exceeding 20 billion yuan to professional investors. Additionally, Hengshi Technology's controlling shareholder, Xinji Group, plans to increase its holdings by 1.5%-3%.

Regarding trading halts and resumptions, ST Xinya has completed its delisting and resumed trading, while Zhitexin Material was suspended for investigation after a 199% increase from January 5 to 12; Mingyang Smart Energy, Shimao Energy, Jianghua Microelectronics, and Huashi Technology have all been suspended due to plans for control rights changes. Market enthusiasm continues to rise.